Contemporary American Dermatology : Continuing Medical Education

ing & Indexing: The journal is indexed in Index Medicus/MEDLINE. Pulse Marketing & Communications, LLC 4 Peninsula Avenue • Suite 401 • Sea Bright, NJ 07760 • Tel (732) 747-6525 • Fax (732) 747-7010 Corporate Publishing Editorial BRIEF SUMMARY Rx ONLY INDICATIONS AND USAGE: Naftin® Cream, 1% is indicated for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. Naftin® Gel, 1% is indicated for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans*, Epidermophyton floccosum*. *Efficacy for this organism in this organ system was studied in fewer than 10 infections. CONTRAINDICATIONS: Naftin® Cream and Gel, 1% are contraindicated in individuals who have shown hypersensitivity to any of their components. WARNINGS: Naftin® Cream and Gel, 1% are for topical use only and not for ophthalmic use. PRECAUTIONS: General: Naftin® Cream and Gel, 1%, are for external use only. If irritation or sensitivity develops with the use of Naftin® Cream or Gel, 1%, treatment should be discontinued and appropriate therapy instituted. Diagnosis of the disease should be confirmed either by direct microscopic examination of a mounting of infected tissue in a solution of potassium hydroxide or by culture on an appropriate medium. Information for patients: The patient should be told to: 1. Avoid the use of occlusive dressings or wrappings unless otherwise directed by the physician. 2. Keep Naftin® Cream and Gel, 1% away from the eyes, nose, mouth and other mucous membranes. Carcinogenesis, mutagenesis, impairment of fertility: Long-term studies to evaluate the carcinogenic potential of Naftin® Cream and Gel, 1% have not been performed. In vitro and animal studies have not demonstrated any mutagenic effect or effect on fertility. Pregnancy: Teratogenic Effects: Pregnancy Category B: Reproduction studies have been performed in rats and rabbits (via oral administration) at doses 150 times or more than the topical human dose and have revealed no evidence of impaired fertility or harm to the fetus due to naftifine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Naftin® Cream or Gel,1% are administered to a nursing woman. Pediatric use: Safety and effectiveness in pediatric patients have not been established. ADVERSE REACTIONS: During clinical trials with Naftin® Cream, 1%, the incidence of adverse reactions was as follows: burning/stinging (6%), dryness (3%) erythema (2%), itching (2%), local irritation (2%). During clinical trials with Naftin® Gel, 1%, the incidence of adverse reactions was as follows: burning/stinging (5.0%), itching (1.0%), erythema (0.5%), rash (0.5%), skin tenderness (0.5%). Manufactured for Merz Pharmaceuticals, Greensboro, NC 27410 © 2010 Merz Pharmaceuticals Rev 3/10 skinmedbriefPI.indd 1 6/11/10 12:05 PM gENERAL COUNSEL Marianne Mckenzie [email protected] May/June 2010 EDITORIAL BOARD 133 Mohamed Amer, MD Cairo, Egypt Robert L. Baran, MD Cannes, France Anthony V. Benedetto, DO Philadelphia, PA Brian Berman, MD, PhD Miami, FL Jack M. Bernstein, MD Dayton, OH Sarah Brenner, MD Tel Aviv, Israel Joaquin Calap Calatayud, MD Cadiz, Spain Henry H.L. Chan, MB, MD, PhD, FRCP Hong Kong, China Ncoza C. Dlova, MBChB, FCDerm Durban, South Africa Richard L. Dobson, MD Mt Pleasant, SC William H. Eaglstein, MD Palo Alto, CA Boni E. Elewski, MD Birmingham, AL Charles N. Ellis, MD Ann Arbor, MI Howard A. Epstein, PhD Gibbstown, NJ Ibrahim Hassan Galadari, MD, PhD, FRCP Dubai, United Arab Emirates Anthony A. Gaspari, MD Baltimore, MD Michael Geiges, MD Zurich, Switzerland Michael H. Gold, MD Nashville, TN Orin M. Goldblum, MD Abbott Park, IL Lowell A. Goldsmith, MD, MPH Chapel Hill, NC Aditya K. Gupta, MD, PhD, FRCP(C) London, Ontario Seung-Kyung Hann, MD, PhD Seoul, Korea Roderick J. Hay, BCh, DM, FRCP, FRCPath London, UK Tanya R. Humphreys, MD Philadelphia, PA Camila K. Janniger, MD Englewood, NJ Abdul-Ghani Kibbi, MD Beirut, Lebanon W. Clark Lambert, MD, PhD Newark, NJ Andrew P. Lazar, MD Highland Park, IL Jasna Lipozencic, MD, PhD Zagreb, Croatia George M. Martin, MD Kihei, HI David I. McLean, MD Vancouver, British Columbia Marc S. Micozzi, MD, PhD Bethesda, MD George F. Murphy, MD Boston, MA Oumeish Youssef Oumeish, MD, FRCP Amman, Jordan Joseph L. Pace, MD, FRCP Naxxar, Malta Art Papier, MD Rochester, NY Vesna Petronic-Rosic, MD, MSc Chicago, IL Johannes Ring, MD, DPhil Munich, Germany Roy S. Rogers III, MD Rochester, MN Donald Rudikoff, MD New York, NY Robert I. Rudolph, MD Wyomissing, PA Vincenzo Ruocco, MD Naples, Italy Noah S. Scheinfeld, MD, JD New York, NY Virendra N. Sehgal, MD Delhi, India J. Graham Smith Jr, MD Mobile, AL Charles Steffen, MD Oceanside, CA Alexander J. Stratigos, MD Athens, Greece James S. Studdiford III, MD Philadelphia, PA Robert J. Thomsen, MD Los Alamos, NM Julian Trevino, MD Dayton, OH Sandy Sharon Tsao, MD Boston, MA Snejina Vassileva, MD, PhD Sofia, Bulgaria Daniel Wallach, MD Paris, France Michael A. Waugh, MB, FRCP Leeds, UK Wm. Philip Werschler, MD Spokane, WA Joseph A. Witkowski, MD Philadelphia, PA Ronni Wolf, MD Rechovot, Israel EDITOR IN CHIEF EDITORIAL BOARD DEPUTY EDITORS William Abramovits, MD Dallas, TX Larry E. Millikan, MD Meridian, MS Jennifer L. Parish, MD Philadelphia, PA Marcia Ramos-e-Silva, MD, PhD Rio de Janeiro, Brazil Lawrence Charles Parish, MD, MD (Hon) Philadelphia, PA May/June 2010 Volume 8 • Issue 3 134 From the Department of Pathology, Divisions of Dermatopathology and Anatomic Pathology; the Department of Dermatology, University of Medicine and Dentistry of New Jersey–New Jersey Medical School, Newark, NJ;1 and the Department of Dermatology and Cutaneous Biology and the Jefferson Center for International Dermatology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA2 Address for Correspondence: W. Clark Lambert, MD, PhD, Room C520, Medical Science Building, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103 • E-mail: [email protected] Continuing medical education (CME) continues to be among the buzzwords of the 21st century. Physicians are subject to penalties for not completing a specified number of hours of CME in a calendar year. Medical societies continue to thrive on providing CME programs, while medical schools have deans whose sole responsibilities are CME programs.